Chronic Pelvic Pain in Medical Education: A Needs Assessment of British Columbian Health Care Providers-in-Training.
Chronic pelvic pain (CPP) affects ∼15% of women and gender-diverse people, yet it is often dismissed by healthcare providers partly due to lack of related medical education. This brief communication …
Corrigendum to "Decreased expression of KLF6 in ectopic endometrial stromal cells contributes to endometriosis progression by targeting CTNNB1" [Cellular Signalling 120 (2024) 111230].
The AGE-RAGE Pathway in Endometriosis: A Focused Mechanistic Review and Structured Evidence Map.
High Mobility Group Box 1 (HMGB1) and S100 proteins are major ligands of Receptor for Advanced Glycation End-products (RAGE) and have causal roles in endometriosis lesions. Yet the AGE-RAGE pathway …
Barriers affecting medication adherence to dienogest among patients with ovarian endometriosis: a qualitative study.
To explore barriers affecting medication adherence (e.g., missed doses, forgotten doses, or discontinuation) among patients with Ovarian Endometriosis (OE) using the Capability, Opportunity, Motivation - Behaviour (COM-B) behavioural change model …
Gut microbiota as a key regulator in endometriosis: mechanisms, therapeutic opportunities, and future perspectives.
Endometriosis (EMs), a common and frequently occurring gynecological disease, is a major cause of chronic pelvic pain and infertility in women. Its pathogenesis remains unclear to date, and it is …
Safety evaluation of percutaneous intrauterine hydrodissection in microwave ablation of uterine fibroids adjacent to the endometrium.
To assess the safety and efficacy of percutaneous intrauterine hydrodissection as a protective technique during microwave ablation (MWA) of uterine fibroids adjacent to the endometrium.
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - The Manila Times
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan The Manila Times